Sideris Pharmaceuticals Completes $32 Million Equity Financing and Signs Agreement With Global Pharmaceutical Company

Posted by on Oct 23, 2013 in Newsroom, Regional Venture News | 0 comments

GAINESVILLE, FL – Sideris Pharmaceuticals, Inc., announced today that it has successfully completed a $32 million Series A equity financing. This investment was led by MPM Capital, including MPM’s SunStates Fund. Also participating in this financing were Hatteras Venture Partners and Osage University Partners. Alongside the equity financing, Sideris entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive right to acquire Sideris and its lead asset, the iron-chelating candidate SP-420. Including upfront, acquisition and milestone payments,...

Read More

Phthisis Diagnostics Acquired by Microbiologics

Posted by on Oct 22, 2013 in Newsroom, Regional Venture News | 0 comments

Charlottesville, VA – Phthisis Diagnostics has announced its acquisition by Microbiologics, a St. Cloud, Minnesota-based company.  Phthisis’ innovative, patented G-Sphere® molecular standards product line will be the foundation for Microbiologics’ launch into molecular products and a new division it is forming for this fresh direction.  G-Sphere® standards are synthetic genes that provide safe, stable, consistent, and abundant controls for virtually any organism or molecular assay. Crystal Icenhour, PhD, President and Chief Science Officer at Phthisis since 2006, created this new...

Read More

G1 Therapeutics Raises $12.5M Series A Financing Led by MedImmune Ventures

Posted by on Oct 16, 2013 in Newsroom, Regional Venture News | 0 comments

CHAPEL HILL, NC –  G1 Therapeutics, Inc. today announced that it has raised a Series A financing of $12.5M that will enable the advancement of its lead clinical candidate through the filing of an Investigational New Drug application (IND) and initial clinical testing. The financing was led by MedImmune Ventures. Co-investors include Hatteras Venture Partners and Mountain Group Capital.  Michael Gutch, Ph.D., Managing Director, MedImmune Ventures, and Ron Laufer, M.D., M.P.H., Senior Managing Director, MedImmune Ventures, have joined G1’s board of directors. G1’s lead...

Read More

Aerie Pharma craves $84.5M in amped-up offering as IPOs pour in

Posted by on Oct 15, 2013 in Newsroom, Regional Venture News | 0 comments

RESEARCH TRIANGLE PARK, NC – Aerie Pharmaceuticals is scaling up its IPO target, seeking $84.5 million to bankroll the development of its glaucoma treatments, and the company is counting on the burgeoning public market for biotechs to line its pockets. In a boost over the $57.5 million it filed for in September, Aerie now plans to sell about 5.3 million shares at between $12 and $14 apiece, netting up to $69.5 million if its underwriters come through in the end. Of that cash, Aerie plans to put $34 million to fund Phase III for AR-13324, a topical treatment for open-angle glaucoma...

Read More

iScreen Vision Closes $4.0 Million in Series B Funding to Expand Its Pediatric Vision Screening Solutions to New Markets

Posted by on Oct 9, 2013 in Newsroom, Regional Venture News | 0 comments

MEMPHIS, TN – iScreen Vision, Inc., a leading provider of pediatric vision screening equipment and services, today announced it raised $4.0 million in a Series B funding round led by MB Venture Partners. “iScreen Vision is well positioned to capture a significant share of the pediatric vision screening market with its patented cloud-based system” The latest round raised $2.5 million in new money and converted $1.5 million of debt into Series B shares for a total round of $4.0 million. Investors in the round included MB Venture Partners, a new investor in iScreen Vision; Innova,...

Read More

Mako Surgical to make acquisition before it’s bought out

Posted by on Oct 7, 2013 in Newsroom, Regional Venture News | 0 comments

DAVIE, FL – Before Mako Surgical Corp. is bought out for $1.65 billion, it plans to complete an acquisition of its own. The Davie-based manufacturer of a knee and hip replacement surgical robot (NASDAQ: MAKO) announced that it would acquire the orthopedic device and robotics line of Cedar Knolls, N.J.-based Pipeline Biomedical Holdings. These products were developed by its Pipeline Orthopedics affiliate. In addition to knee and hip replacements, it also develops shoulder replacements. Mako Surgical said Pipeline Biomedical has been its partner in developing and supplying advanced...

Read More